neurocoach.
My Care Plan

BIPOLAR I DEPRESSION · NEUROMODULATION · OCTOBER 16, 2026

Could a full TMS course fit into one day? Promising results, significant unknowns.

Thirty adults with bipolar I depression received a rapid, single-day combination of brain stimulation and a study medication. Many reported improvement six weeks later—but there was no placebo or usual-care control group, so the treatment's effectiveness remains unproven.

Small open-label case series30 adults; no control groupExperimental combination protocol
Research updates →Compare available and emerging care
Reading list (0) →

Saved in this browser. Sign in to sync across devices.

Important dating and status note: The ONE-BD paper was published online August 19, 2026; a company highlighted it again on October 15. It is not a new October randomized clinical trial. The specific accelerated TMS-plus-medication protocol studied is not an established or FDA-authorized treatment for bipolar depression. Any brain-stimulation decision requires specialist assessment and monitoring.

What did the study actually involve?

Researchers reported outcomes for 30 adults with bipolar I disorder during a depressive episode. All participants received multiple, brief intermittent theta-burst stimulation sessions during a single supervised day, alongside D-cycloserine, a medication being studied for its potential to influence neuroplasticity. The combination—not TMS alone—was being evaluated.

Every participant finished the treatment day and was followed for up to 12 weeks. The report was an uncontrolled, open-label case series rather than a randomized trial.

SIX-WEEK RESPONSE

73.3%

22 of 30 met the study's response threshold on the clinician-rated Hamilton Depression Rating Scale (HDRS-17). This is a proportion within the study, not a proven effectiveness rate.

SIX-WEEK REMISSION

43.3%

13 of 30 met the study's remission threshold on HDRS-17. Without a comparison group, investigators cannot determine how much improvement the combination caused.

SHORT-TERM SAFETY

0 observed mania switches

No mania or hypomania switches were reported among these 30 participants during follow-up. A small sample cannot rule out rare or longer-term adverse outcomes.

EVIDENCE QUALITY

No sham control

The design cannot separate treatment effects from placebo effects, spontaneous mood changes, selection effects, concurrent treatment or measurement influences.

Why might a single-day treatment matter?

Conventional outpatient TMS for its established indications often involves repeated clinic visits over several weeks. A shorter effective treatment could reduce time away from work, caregiver logistics and travel burdens. But reducing the number of visits is only an advantage if larger controlled trials demonstrate that outcomes and safety are acceptable.

What is already established—and what is not?

Brain-stimulation treatments have different evidence and regulatory statuses for different conditions. For example, specific TMS devices and schedules are FDA-cleared for selected depression indications, and electroconvulsive therapy (ECT) can be used for severe bipolar episodes in appropriate clinical settings. Neither fact authorizes this experimental ONE-BD protocol or demonstrates that it works for bipolar depression.

Clinicians also need to consider the possibility of mood switching, other medications, seizure history, medical conditions and the suitability of stimulation for each patient. A research medication should not be added or self-administered to imitate a trial.

What are the main limitations?

  • Small sample: 30 participants cannot establish rare side-effect rates or generalizability.
  • No randomized or sham comparison: Neither efficacy nor the incremental benefit of D-cycloserine can be established.
  • Limited follow-up: The report followed participants for 12 weeks, not years.
  • Combined intervention: It is impossible to tell whether any apparent improvement came from stimulation, the medication, concurrent care or other factors.
  • Clinical selection: Participants treated in a specialist setting may not represent all people with bipolar disorder or overlapping diagnoses.

Questions for a psychiatrist or TMS specialist

  • What evidence-supported options are appropriate for bipolar depression and this person's history?
  • Is a particular TMS device or protocol FDA-cleared for the exact proposed use?
  • What is known about manic switching, monitoring, other medications and treatment durability?
  • If the proposed protocol is experimental, is it part of a registered, ethically reviewed study?

The responsible next step in research

A larger, randomized trial comparing the combination with an appropriate sham or standard-care condition is needed to evaluate benefit, safety and durability. The August publication and October announcement are worth following, but they do not change the standard of care.

Find registered researchHow evidence labels work

Original study and authoritative context

Sources checked October 16, 2026 · Educational editorial draft; independent clinical review pending. Do not alter medications or pursue experimental stimulation outside appropriate clinical care.